^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | IDP-023 (NK cell stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
02/29/2024
Excerpt:
...today announced that the U.S. FDA has granted Fast Track designation for its lead clinical program, IDP-023, for the treatment of patients with non-Hodgkin’s lymphoma and multiple myeloma.
